Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07015190 · ClinicalTrials.gov registry record · Phase 3
Neoadjuvant Darovasertib in Primary Uveal Melanoma
A Phase 3 study of Uveal Melanoma, sponsored by IDEAYA Biosciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 520
- Enrollment target
- 20
- Study locations
NCT07015190 is a Phase 3 study of Uveal Melanoma that is actively recruiting participants, run by IDEAYA Biosciences. The registered enrollment target is 520 participants, above the 127-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (309% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT07015190, a Phase 3 study of Uveal Melanoma, is actively recruiting participants, sponsored by IDEAYA Biosciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 520 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
Conditions Studied
Interventions
- DRUG Darovasertib
- PROCEDURE Primary Local Therapy
Study Locations (20)
California
- UCSD Moores Cancer Center - La Jolla
- Jules Stein Eye Institute - Los Angeles
- University of California Irvine Medical Center - Orange
- Stanford Comprehensive Cancer Center - Palo Alto
- Kaiser Permanente-Riverside Medical Center - Riverside
New York
- Herbert Irving Comprehensive Cancer Center - New York
- Memorial Sloan Kettering Cancer Center - 1275 York Ave - New York
- Northwell Health Cancer Institute - New York
Colorado
- University of Colorado Hospital - Aurora
- The Melanoma and Skin Cancer Institute - Englewood
Florida
- Mayo Clinic Jacksonville - Jacksonville
- USF Health Eye Institute - Tampa
Michigan
- W Kellogg Eye Center - Ann Arbor
- The Cancer and Hematology Centers of West Michigan (CHCWM) - Grand Rapids
Arizona
- Mayo Clinic Scottsdale - PPDS - Scottsdale
Maryland
- Wilmer Eye Institute - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2026-01-25 |
| Est. Completion | 2031-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07015190
The ClinicalTrials.gov registry entry for NCT07015190 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 520 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 127-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (309% higher). The listed sponsor is IDEAYA Biosciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Uveal Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Darovasertib is the first listed.
NCT07015190 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, New York, Colorado.
Frequently Asked Questions
What is clinical trial NCT07015190 about?
NCT07015190 is a clinical study titled "Neoadjuvant Darovasertib in Primary Uveal Melanoma". This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
What is the current status of trial NCT07015190?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 520 participants. The study started on 2026-01-25. Estimated completion is 2031-03.
What conditions does trial NCT07015190 study?
This clinical trial studies the following conditions: Uveal Melanoma.
What interventions are being tested in trial NCT07015190?
The interventions under investigation include: Darovasertib (DRUG), Primary Local Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT07015190?
This trial is sponsored by IDEAYA Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07015190 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
RECRUITING · Phase 3
-
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
COMPLETED · Phase 3
-
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
RECRUITING · NA
-
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.